Welcome to our dedicated page for Genenta Science S.p.A. news (Ticker: GNTA), a resource for investors and traders seeking the latest updates and insights on Genenta Science S.p.A. stock.
Genenta Science S.p.A. reports developments spanning its biotechnology heritage and its strategic shift toward an industrial consolidation model in Italian national-security-regulated sectors. News items cover the company’s Nasdaq-traded ADSs, capital structure, operating and financial results, and governance actions tied to the expanded corporate purpose approved under Italy’s Golden Power framework.
Company updates also include the Temferon hematopoietic stem-cell gene therapy platform for solid tumors, clinical findings in glioblastoma multiforme, and efforts to evaluate collaboration opportunities for the biotechnology platform. Recent corporate news has also addressed defense, aerospace, cybersecurity, biotechnology, and biosecurity themes as Genenta evaluates and pursues industrial integrations.
Genenta Science (NASDAQ: GNTA) has enhanced its partnership with AGC Biologics by securing an exclusive GMP manufacturing suite at AGC's Cell and Gene Center of Excellence in Milan. This strategic amendment aims to strengthen the production of Genenta's cell therapy products, ensuring cGMP compliance.
The company's metastatic Renal Cell Cancer (mRCC) Phase 1/2a trial, initiated in Q4 2024, aims to treat six patients by H1 2025, while the Glioblastoma Multiforme (GBM) study continues. Genenta plans to manufacture 27 autologous drug products in 2025.
Recent preclinical and clinical studies highlight Temferon's capability to reprogram the tumor microenvironment, inhibit myeloid cell-induced immune suppression, and enhance T-cell responses. The company suggests potential synergies with immunotherapeutic strategies, including immune checkpoint inhibitors and CAR-T cell therapies.
The Italian Trade Agency (ITA) and the Ministry of Foreign Affairs will host the eighth 'Italy on the Move' event alongside the 43rd J.P. Morgan Healthcare Conference 2025 in San Francisco. The event, scheduled for January 15, 2025, at INNOVIT, aims to showcase Italy's €270 billion life sciences sector and investment opportunities.
The Italian life sciences ecosystem, contributing 11% to the country's GDP, has attracted nearly 50 multinational companies. Italy ranks first among EU economies in pharma CDMO manufacturing value and fourth worldwide in Life Sciences patents productivity.
The event will feature keynote speakers including Ambassador Mariangela Zappia and Director General Mauro Battocchi, followed by a panel discussion on 'Navigating Transatlantic Partnerships in Life Sciences' moderated by Audrey Greenberg. Notable panelists include executives from Rubedo Life Sciences, Bracco Imaging, Menarini Group, TPG Capital, and Genenta Science (NASDAQ: GNTA). Five Italian startups - Aavantgarde, Butterfly Decisions, Cellply, Medlea, and Sibylla Biotech - will present pitch presentations.
Genenta Science (NASDAQ: GNTA) announces CEO Pierluigi Paracchi's participation as a speaker at the Italy-U.S. meeting on 'Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective' at the U.S. Senate on October 25th, 2024. The event, organized by the U.S. National Security Commission on Emerging Biotechnology and Italian Embassy, features distinguished speakers including Michelle Rozo, Mariangela Zappia, and Patrick Soon-Shiong.
As moderator of the Italian Working Group on Internationalization of Biotech Sector (NWTIB), Paracchi will present the Interim Report, emphasizing the strategic importance of biotechnologies post-pandemic and Italy's role in preserving and advancing these innovations while attracting international investments.
Genenta Science (NASDAQ: GNTA) has received approval from AIFA for a new Phase 1 clinical trial for metastatic Renal Cell Cancer (mRCC), expanding potential applications for its flagship product, Temferon™. This approval aligns with EMA standards. The company's ongoing TEM-GBM development program has completed a Phase 1 dose-ranging trial, confirming no dose-limiting toxicities across 24 patients. Temferon-derived cells remained detectable for over two years post-infusion, with treatment associated with a median survival of 16.8 months and a 25% increase in 2-year overall survival.
The new mRCC trial, targeting high-risk patients with a median overall survival of less than 2 years after multiple therapies, is expected to start in Q4 2024. Recent preclinical studies show synergy between Temferon and other immunotherapies in solid tumors. Genenta will present these developments at upcoming events, including Maxim Group's 2024 Healthcare Virtual Summit and the Society for Neuro-Oncology Annual Meeting.
Genenta Science (NASDAQ: GNTA) recently appointed five new directors to its Board of Directors, including John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider. The company aims to leverage the expertise of these new members to further develop its cell-based platform for treating solid tumors. The shareholders' meeting held on May 2, 2024, marked a significant step towards strengthening the company's leadership and strategic direction.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.